Messenger RNA
Messenger RNA (mRNA) is a single-stranded ribonucleic acid transcribed from a DNA template, carrying in its codons the instructions the ribosome reads to assemble a polypeptide.
Messenger RNA (mRNA) is a single-stranded ribonucleic acid transcribed from a DNA template, carrying in its codons the instructions the ribosome reads to assemble a polypeptide. In eukaryotes the primary transcript is processed before it can be used: a 7-methylguanosine CAP is added at the 5′ end, introns are excised and exons joined by the spliceosome, and the 3′ end is cleaved and polyadenylated. Alternative splicing means one gene can yield several distinct mRNAs and so several proteins. The mature molecule is modular — a 5′ untranslated region, an open reading frame, and a 3′ untranslated region carrying the binding sites for microRNAs and RNA-binding proteins that set stability and translation rate — and the CAP and poly(A) tail together license translation and protect the ends from exonucleases. The pattern is near-universal rather than absolute: replication-dependent histone mRNAs end in a conserved stem-loop instead of a poly(A) tail, and bacterial mRNA, lacking a nucleus, is translated while still being transcribed.
An mRNA is a transient intermediate by design. Deadenylation followed by decapping and exonucleolytic decay gives most transcripts a half-life of hours, surveillance pathways such as nonsense-mediated decay destroy those bearing premature stop codons, and translation itself is regulated at initiation. Most of this occurs in the cytoplasm, though mitochondria transcribe and translate their own mRNAs, and some transcripts have documented nuclear roles. Because the molecule is read and then destroyed without entering the genome, the mRNA itself is temporary, although the proteins it produces can cause lasting effects, including heritable genomic changes — the property that makes it attractive as a drug.
Synthetic mRNA can be designed to encode essentially any protein, with substitution of uridine by N1-methylpseudouridine and tuning of the untranslated regions used to raise translation and blunt innate immune sensing. Its size and polyanionic charge prevent it from crossing membranes unaided, so mRNA drugs are almost always formulated in a carrier — most commonly lipid nanoparticle built from an ionizable lipid such as ALC-0315 together with phospholipid, cholesterol, and PEGylated lipid. The ionizable lipid binds mRNA at low pH during assembly and is protonated again inside the endosome, promoting escape into the cytosol; endosomal entrapment remains the principal bottleneck limiting delivery, and ionizable lipid chemistry also drives dose-limiting toxicity and proinflammatory cytokine responses. Polymeric micelles, electroporation of unformulated RNA, and biologically assembled vectors are alternative routes under investigation. Clinically, mRNA is best established in mRNA-based COVID-19 vaccines, and is being extended to in situ engineering of T-lymphocytes for CAR T cell therapy, transfection of stromal populations such as fibroblasts and macrophages within the tumor microenvironment, regenerative applications in skin, and delivery of genome-editing components including CRISPR-associated protein 9 (Cas9) mRNA and CRISPR-Cas12a systems.
Where the papers sit
34 papers from the last 6 months study Messenger RNA directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 1 observational · 3 human data · 17 preclinical · 13 unclassified
Themes 5 themes · 1 paradigm shift
-
mRNA Delivery Platforms
Lipid nanoparticles are being tuned to raise mRNA copy number, protein-expression potency, storage stability, and tissue selectivity. Process variables such as dilution mode, lipid composition, and neutral amphiphiles shape assembly, inflammation, biodistribution, and elimination. Hepatocyte- and integrin-targeted particles, pharmacokinetic models, and muscle delivery extend work beyond liver exposure. The payloads span vaccines, erythropoietin, and tumor therapeutics, while expression kinetics remain a central endpoint.
16 papers · 47.1%
-
Targeted mRNA Nanoparticle Delivery
Targeted nanoparticle design is moving mRNA delivery toward difficult tissues and selected cell types rather than passive exposure. CNS-accessing particles address the blood-brain barrier, while CD2/CD7 targeting favors primary CD4+ T cells and fibroblast-selective particles address tumor stroma. Single-particle counting and linker-controlled transcripts add control over dose and payload integrity. Virus-like particle expression extends the platform to enterovirus D68 vaccination.
6 papers · 17.6%
-
Targeted mRNA Cancer Therapy
Cancer mRNA nanotherapy is moving toward targeted reprogramming of tumors and their immune microenvironment. Liver-tumor transfection, tumor-associated macrophage targeting, and PGC1α expression aim to improve cytotoxic T-lymphocyte activity or restrain prostate cancer. Endosomal-barrier disruption is treated as a key determinant of therapeutic potency, including mechanically movable lipids. Metabolic reprogramming also appears in ischemic cardiac injury, so the cluster extends beyond oncology without a single shared efficacy endpoint.
5 papers · 14.7%
-
mRNA Vaccine Development
mRNA vaccine development is pairing safer, more manufacturable delivery with attention to public trust and pandemic readiness. Tail-modified ionizable lipids, antioxidant formulations, and piezoelectric delivery seek to improve tolerability or avoid conventional encapsulation. Nanopore assembly targets precise, continuous production of vaccine lipid nanoparticles, including COVID-19 applications. The cluster links technical optimization with acceptance rather than establishing a single clinical efficacy direction.
4 papers · 11.8%
-
Dry Powder mRNA Formulation
Thin-film freezing and lyophilization are being optimized to convert mRNA lipid nanoparticles and polyplexes into inhalable dry powders. The recurring targets are encapsulation efficiency, particle size, excipient composition, and preservation of transfection activity. Freezing-induced loss of internal structure is linked to poorer in vitro performance, making solid-state organization a critical quality attribute. The work is converging on stable pulmonary formulations rather than liquid products alone.
3 papers · 8.8%
Effective mRNA delivery does not require lipid nanoparticles
The Piezopen naked RNA vaccine study and the RNA-BEV skin-regeneration study assume that effective mRNA delivery requires a lipid nanoparticle carrier, but they instead show that skin-targeted electroporation can make naked mRNA produce immune responses comparable to LNPs, while biologically engineered vectors can outperform mRNA-loaded LNPs in a diabetic-wound model 42412769Jul 42420582Jul. This changes the delivery framework by making LNPs one option rather than a necessary platform for functional mRNA expression.
Papers
The 34 papers from the last 6 months that study Messenger RNA directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
mRNA Delivery Platforms (16)
- Protein expression kinetics of mRNA, saRNA, and pDNA as individual or co-delivered payloads using a common lipid nanoparticle formulation. Journal of controlled release : official journal of the Controlled Release Society · 28 Sept 2026 PMID 42805567
- Increasing Lipid Nanoparticle mRNA Copy Number Improves Transfection Potency. Advanced materials (Deerfield Beach, Fla.) · 28 Sept 2026 PMID 42802644
- Dilution mode acts as a critical process parameter that reprograms lipid nanoparticle assembly and in vivo mRNA delivery. Journal of controlled release : official journal of the Controlled Release Society · 16 Sept 2026 PMID 42749133
- A Bioorthogonal Desilylation System Potentiates mRNA Therapeutics in Tumors. Journal of the American Chemical Society · 20 Aug 2026 PMID 42619087
- MAPT splicing modulators reduce 4R tau and rescue tauopathy phenotypes in human neurons and in a mouse model. Science translational medicine · 19 Aug 2026 PMID 42616837
- Hyperbranched Polylysine-Based Lipopolyplexes Enable Efficient mRNA Delivery With Long-Term Storage Stability. Advanced healthcare materials · 13 Aug 2026 PMID 42590857
- Comparative Elimination Analysis of Lipid Nanoparticle-Encapsulated Human Erythropoietin mRNA by Multimodal Approaches Suggests an Effective Doping Control Strategy for mRNA-Based Agents. Drug testing and analysis · 3 Aug 2026 PMID 42547045
- Isoquercitrin suppresses neuronal ferroptosis in ischemic stroke via SIRT1-mediated deacetylation of H3K9 at the RBM15 promoter. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 3 Aug 2026 PMID 42545594
- Survival Impact of Programmed Cell Death Ligand-1 Expression in Patients With Epithelial Ovarian Carcinoma. Cancer reports (Hoboken, N.J.) · 30 Jul 2026 PMID 42530487
- Construction of a translational whole-body physiologically based pharmacokinetic model to investigate the biodistribution of lipid nanoparticle-based mRNA therapeutics for intracellular protein targets. Journal of pharmacokinetics and pharmacodynamics · 29 Jul 2026 PMID 42527729
- Neutral Amphiphiles Boost Transfection Efficiency and Reduce Inflammation in Polymer Micelle-Mediated mRNA Delivery. Bioconjugate chemistry · 2 Jul 2026 PMID 42391639
- Muscle contribution in lipid nanoparticle mediated mRNA vaccine delivery and efficacy. Journal of controlled release : official journal of the Controlled Release Society · 30 Jun 2026 PMID 42379311
- Bivalent foot-and-mouth disease virus mRNA vaccine induces well-balanced humoral and cellular immune responses. Vaccine · 19 Jun 2026 PMID 42320384
- Secondary Site Ligand for Integrin αVβ3 Enables Targeted mRNA Delivery. Angewandte Chemie (International ed. in English) · 18 Jun 2026 PMID 42313784
- Targeting and traceability of DY635-functionalized lipids for cholesterol-free, hepatocyte-directed lipid nanoparticles. International journal of pharmaceutics · 17 Jun 2026 PMID 42309200
- Interference of target protein translation in multivalent mRNA vaccine in cell-based assay. Journal of pharmaceutical and biomedical analysis · 22 May 2026 PMID 42173746
Targeted mRNA Nanoparticle Delivery (6)
- Linker-mediated single-transcript mRNA vaccine expressing virus-like particles of enterovirus D68. Vaccine · 10 Sept 2026 PMID 42721891
- Overcoming the blood-brain barrier using central nervous system-accessing lipid nanoparticles for enhanced mRNA therapeutics. Proceedings of the National Academy of Sciences of the United States of America · 14 Aug 2026 PMID 42599788
- Fibroblast-Selective Lipid Nanoparticles for Tumor Stromal Transfection. Molecular pharmaceutics · 16 Jul 2026 PMID 42458928
- Biologically engineered vectors enable topical mRNA delivery for skin regeneration. Communications biology · 8 Jul 2026 PMID 42420582
- Targeting rapidly cycling receptors CD2 and CD7 increases nanoparticle delivery to primary CD4+ T cells. Nature communications · 1 Jul 2026 PMID 42386746
- Direct Counting of mRNA Copies Inside Individual Lipid Nanoparticles Using In Situ Lysis and Labeling. Analytical chemistry · 29 May 2026 PMID 42210530
Targeted mRNA Cancer Therapy (5)
- Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
- Loss of eIF3m aggravates myocardial ischemia/reperfusion injury via enhancing nitrative damage and inhibiting glycolytic reprogramming. Science bulletin · 22 Aug 2026 PMID 42632795
- Systemically delivered mRNA-LNPs transfect primary and secondary liver tumors. Molecular therapy. Nucleic acids · 13 Jul 2026 PMID 42440881
- Mechanical movements generated by movable lipids break endosomal barriers for enhanced mRNA therapeutics. Science advances · 1 Jul 2026 PMID 42384808
- PGC1α expression using targeted redox-responsive nanogels protects against prostate cancer in vivo. Journal of controlled release : official journal of the Controlled Release Society · 29 Jun 2026 PMID 42372825
mRNA Vaccine Development (4)
- Healthy Trust and Pandemic Readiness in the Context of Messenger RNA Vaccines: Protocol for a Sequential Deliberative Dialogue Study. JMIR research protocols · 25 Sept 2026 PMID 42789402
- Nanopore-Mediated Assembly Enables Precise and Continuous Synthesis of mRNA-Encapsulated Lipid Nanoparticles for COVID-19 Vaccines. ACS nano · 16 Jul 2026 PMID 42462004
- Optimized Lipid Nanoparticles with Tail-Modified Ionizable Lipids for Safer mRNA Delivery. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 14 Jul 2026 PMID 42446186
- A piezoelectric electroporator (Piezopen) for enhanced "naked" RNA vaccine delivery. PloS one · 7 Jul 2026 PMID 42412769
Dry Powder mRNA Formulation (3)
- Effect of thin-film freezing process parameters and excipient composition on mRNA lipid nanoparticles in inhalable powders. International journal of pharmaceutics · 18 Aug 2026 PMID 42612848
- Inhaled dry powders of mRNA polyplexes prepared by thin-film freeze-drying. International journal of pharmaceutics · 17 Aug 2026 PMID 42607969
- Loss of internal structural order induced by freezing and lyophilization correlates with reduced in vitro activity of mRNA lipid nanoparticles. Journal of controlled release : official journal of the Controlled Release Society · 30 Jun 2026 PMID 42379312
By study type
Observational studies and case reports (1)
- Survival Impact of Programmed Cell Death Ligand-1 Expression in Patients With Epithelial Ovarian Carcinoma. Cancer reports (Hoboken, N.J.) · 30 Jul 2026 PMID 42530487
Human data, design not indexed (3)
- Healthy Trust and Pandemic Readiness in the Context of Messenger RNA Vaccines: Protocol for a Sequential Deliberative Dialogue Study. JMIR research protocols · 25 Sept 2026 PMID 42789402
- Secondary Site Ligand for Integrin αVβ3 Enables Targeted mRNA Delivery. Angewandte Chemie (International ed. in English) · 18 Jun 2026 PMID 42313784
- Interference of target protein translation in multivalent mRNA vaccine in cell-based assay. Journal of pharmaceutical and biomedical analysis · 22 May 2026 PMID 42173746
Preclinical: animal, cell and lab studies (17)
- Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
- Loss of eIF3m aggravates myocardial ischemia/reperfusion injury via enhancing nitrative damage and inhibiting glycolytic reprogramming. Science bulletin · 22 Aug 2026 PMID 42632795
- A Bioorthogonal Desilylation System Potentiates mRNA Therapeutics in Tumors. Journal of the American Chemical Society · 20 Aug 2026 PMID 42619087
- MAPT splicing modulators reduce 4R tau and rescue tauopathy phenotypes in human neurons and in a mouse model. Science translational medicine · 19 Aug 2026 PMID 42616837
- Inhaled dry powders of mRNA polyplexes prepared by thin-film freeze-drying. International journal of pharmaceutics · 17 Aug 2026 PMID 42607969
- Overcoming the blood-brain barrier using central nervous system-accessing lipid nanoparticles for enhanced mRNA therapeutics. Proceedings of the National Academy of Sciences of the United States of America · 14 Aug 2026 PMID 42599788
- Comparative Elimination Analysis of Lipid Nanoparticle-Encapsulated Human Erythropoietin mRNA by Multimodal Approaches Suggests an Effective Doping Control Strategy for mRNA-Based Agents. Drug testing and analysis · 3 Aug 2026 PMID 42547045
- Isoquercitrin suppresses neuronal ferroptosis in ischemic stroke via SIRT1-mediated deacetylation of H3K9 at the RBM15 promoter. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 3 Aug 2026 PMID 42545594
- Construction of a translational whole-body physiologically based pharmacokinetic model to investigate the biodistribution of lipid nanoparticle-based mRNA therapeutics for intracellular protein targets. Journal of pharmacokinetics and pharmacodynamics · 29 Jul 2026 PMID 42527729
- A piezoelectric electroporator (Piezopen) for enhanced "naked" RNA vaccine delivery. PloS one · 7 Jul 2026 PMID 42412769
- Neutral Amphiphiles Boost Transfection Efficiency and Reduce Inflammation in Polymer Micelle-Mediated mRNA Delivery. Bioconjugate chemistry · 2 Jul 2026 PMID 42391639
- Mechanical movements generated by movable lipids break endosomal barriers for enhanced mRNA therapeutics. Science advances · 1 Jul 2026 PMID 42384808
- Loss of internal structural order induced by freezing and lyophilization correlates with reduced in vitro activity of mRNA lipid nanoparticles. Journal of controlled release : official journal of the Controlled Release Society · 30 Jun 2026 PMID 42379312
- Muscle contribution in lipid nanoparticle mediated mRNA vaccine delivery and efficacy. Journal of controlled release : official journal of the Controlled Release Society · 30 Jun 2026 PMID 42379311
- PGC1α expression using targeted redox-responsive nanogels protects against prostate cancer in vivo. Journal of controlled release : official journal of the Controlled Release Society · 29 Jun 2026 PMID 42372825
- Bivalent foot-and-mouth disease virus mRNA vaccine induces well-balanced humoral and cellular immune responses. Vaccine · 19 Jun 2026 PMID 42320384
- Targeting and traceability of DY635-functionalized lipids for cholesterol-free, hepatocyte-directed lipid nanoparticles. International journal of pharmaceutics · 17 Jun 2026 PMID 42309200
Unclassified: not yet indexed with MeSH (13)
- Protein expression kinetics of mRNA, saRNA, and pDNA as individual or co-delivered payloads using a common lipid nanoparticle formulation. Journal of controlled release : official journal of the Controlled Release Society · 28 Sept 2026 PMID 42805567
- Increasing Lipid Nanoparticle mRNA Copy Number Improves Transfection Potency. Advanced materials (Deerfield Beach, Fla.) · 28 Sept 2026 PMID 42802644
- Dilution mode acts as a critical process parameter that reprograms lipid nanoparticle assembly and in vivo mRNA delivery. Journal of controlled release : official journal of the Controlled Release Society · 16 Sept 2026 PMID 42749133
- Linker-mediated single-transcript mRNA vaccine expressing virus-like particles of enterovirus D68. Vaccine · 10 Sept 2026 PMID 42721891
- Effect of thin-film freezing process parameters and excipient composition on mRNA lipid nanoparticles in inhalable powders. International journal of pharmaceutics · 18 Aug 2026 PMID 42612848
- Hyperbranched Polylysine-Based Lipopolyplexes Enable Efficient mRNA Delivery With Long-Term Storage Stability. Advanced healthcare materials · 13 Aug 2026 PMID 42590857
- Nanopore-Mediated Assembly Enables Precise and Continuous Synthesis of mRNA-Encapsulated Lipid Nanoparticles for COVID-19 Vaccines. ACS nano · 16 Jul 2026 PMID 42462004
- Fibroblast-Selective Lipid Nanoparticles for Tumor Stromal Transfection. Molecular pharmaceutics · 16 Jul 2026 PMID 42458928
- Optimized Lipid Nanoparticles with Tail-Modified Ionizable Lipids for Safer mRNA Delivery. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 14 Jul 2026 PMID 42446186
- Systemically delivered mRNA-LNPs transfect primary and secondary liver tumors. Molecular therapy. Nucleic acids · 13 Jul 2026 PMID 42440881
- Biologically engineered vectors enable topical mRNA delivery for skin regeneration. Communications biology · 8 Jul 2026 PMID 42420582
- Targeting rapidly cycling receptors CD2 and CD7 increases nanoparticle delivery to primary CD4+ T cells. Nature communications · 1 Jul 2026 PMID 42386746
- Direct Counting of mRNA Copies Inside Individual Lipid Nanoparticles Using In Situ Lysis and Labeling. Analytical chemistry · 29 May 2026 PMID 42210530
Written from 34 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-18 by GPT. Corrections: 2026-09-26 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.